Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8

9 clinical trials · Condition

Record	Firm	Date
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153)	M.D. Anderson Cancer Center	2022-02-14
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer (NCT04929392)	City of Hope Medical Center	2022-01-25
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (NCT04660760)	Academic and Community Cancer Research United	2021-06-16
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers (NCT04460937)	National Cancer Institute (NCI)	2021-04-09
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer (NCT04522336)	M.D. Anderson Cancer Center	2020-09-16
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer (NCT04220827)	M.D. Anderson Cancer Center	2019-12-06
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574)	National Cancer Institute (NCI)	2019-07-16
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer (NCT03918499)	City of Hope Medical Center	2019-04-19

Every clearance here is in the API, with alerts when new ones post.